Financials data is unavailable for this security.
View more
Year on year Shanghai Aladdin Biochemical Technology Co Ltd had net income fall -7.48% from 92.77m to 85.83m despite a 6.55% increase in revenues from 378.10m to 402.88m. An increase in the selling, general and administrative costs as a percentage of sales from 19.85% to 19.93% was a component in the falling net income despite rising revenues.
| Gross margin | 61.34% |
|---|---|
| Net profit margin | 23.70% |
| Operating margin | 26.16% |
| Return on assets | 6.79% |
|---|---|
| Return on equity | 10.19% |
| Return on investment | 7.81% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Shanghai Aladdin Biochemical Technology Co Ltd fell by 49.86m. However, the company earned 55.79m from its operations for a Cash Flow Margin of 13.85%. In addition the company used 67.75m on investing activities and also paid 38.01m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 3.70 |
|---|---|
| Tangible book value per share | 3.12 |
More ▼
Balance sheet in CNYView more
| Current ratio | 5.91 |
|---|---|
| Quick ratio | 3.13 |
| Total debt/total equity | 0.3995 |
|---|---|
| Total debt/total capital | 0.2729 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 68.00% and 49.34%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.68% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 58.17% |
| EPS growth(5 years) | 5.92 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 144.52 |
More ▼
